TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Chinese military researchers move a new COVID vaccine candidate into human trial

  • Roxanne Liu and Se Young Lee

    Reuters

Beijing, China   /   Thu, June 25, 2020   /   10:40 am
Chinese military researchers move a new COVID vaccine candidate into human trial A French National Centre for Scientific Research (CNRS) researcher holds up a test tube containing cells to be infected with COVID-19 during coronavirus vaccine research work inside the Pasteur Institute laboratories in Lille, France, on Monday, March 9, 2020.A Chinese military research institute has been approved to test its second experimental coronavirus vaccine in humans, the eighth candidate in clinical trials for China as it emerges as a front-runner in the global fight against COVID-19. (Bloomberg/Adrienne Surprenant)

A Chinese military research institute has been approved to test its second experimental coronavirus vaccine in humans, the eighth candidate in clinical trials for China as it emerges as a front-runner in the global fight against COVID-19.

No vaccine has been approved for sale against the virus that has killed over 470,000 people, but more than a dozen candidates have entered different stages of human test globally.

The new drug is developed by the Academy of Military Science (AMS), a research institute affiliated with the People's Liberation Army, and was approved to proceed to human trial by China's National Medical Products Administration.

AMS' latest candidate, named ARCoV, uses mRNA technology, an approach that is also used for candidates developed by Moderna Inc in the United States and German firm CureVac but has never been tested in China-based clinical trials, the institute said in its social media WeChat late on Wednesday.

"The core raw materials and equipment are all domestically produced, and rapid production capacity ramp-up is achievable," Qin Chengfeng, a researcher responsible for the mRNA project, said in the statement.

The Chinese Clinical Trial registry, without naming ARCoV, said a phase 1 clinical trial for an mRNA vaccine, sponsored by AMS, Yunnan Walvax Biotechnology and Suzhou Abogen Biosciences, would start on Thursday and evaluate the safety of the candidate. http://www.chictr.org.cn/showproj.aspx?proj=55524

Separately, Ad5-nCoV, a vaccine candidate co-developed by AMS and CanSino Biologics using a different technique, is under phase-2 clinical trial in China and has won approval to begin human testing in Canada.